177 related articles for article (PubMed ID: 22770662)
1. Active surveillance for prostate cancer: barriers to widespread adoption.
Sandhu GS; Andriole GL
Eur Urol; 2012 Dec; 62(6):984-5. PubMed ID: 22770662
[No Abstract] [Full Text] [Related]
2. [Active surveillance of low risk prostate cancer].
Weißbach L
Urologe A; 2015 Jun; 54(6):869-70. PubMed ID: 26081819
[No Abstract] [Full Text] [Related]
3. Active Surveillance for Prostate Cancer.
Matulewicz RS; Weiner AB; Schaeffer EM
JAMA; 2017 Dec; 318(21):2152. PubMed ID: 29209723
[No Abstract] [Full Text] [Related]
4. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
[No Abstract] [Full Text] [Related]
5. Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions.
Mullins JK; Carter HB
BJU Int; 2014 Jun; 113(6):844-5. PubMed ID: 24905655
[No Abstract] [Full Text] [Related]
6. [Active surveillance in prostate cancer. Introduction].
Briones JR
Arch Esp Urol; 2014 Jun; 67(5):367-8. PubMed ID: 25039087
[No Abstract] [Full Text] [Related]
7. Active surveillance for early-stage prostate cancer.
Lancet; 2014 Jan; 383(9913):188. PubMed ID: 24439724
[No Abstract] [Full Text] [Related]
8. Active surveillance for clinically localized prostate cancer--a systematic review.
Thomsen FB; Brasso K; Klotz LH; Røder MA; Berg KD; Iversen P
J Surg Oncol; 2014 Jun; 109(8):830-5. PubMed ID: 24610744
[TBL] [Abstract][Full Text] [Related]
9. More men with low risk prostate cancer are opting for active surveillance, study finds.
BMJ; 2016 Oct; 355():i5688. PubMed ID: 27769959
[No Abstract] [Full Text] [Related]
10. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
11. Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer.
Haffty BG; Lawton CA; Sandler H
JAMA Oncol; 2015 Aug; 1(5):688-9. PubMed ID: 26182350
[No Abstract] [Full Text] [Related]
12. Prostate Cancer Active Surveillance: Quality Matters.
Van Veldhuizen PJ
J Natl Compr Canc Netw; 2023 May; 21(5):529-530. PubMed ID: 37156479
[No Abstract] [Full Text] [Related]
13. Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer-Reply.
Williams SB; Chamie K; Hu JC
JAMA Oncol; 2015 Aug; 1(5):689-90. PubMed ID: 26181144
[No Abstract] [Full Text] [Related]
14. When and How Should Active Surveillance for Prostate Cancer be De-Escalated?
Rajwa P; Sprenkle PC; Leapman MS
Eur Urol Focus; 2021 Mar; 7(2):297-300. PubMed ID: 32019719
[TBL] [Abstract][Full Text] [Related]
15. Clinical and policy perspectives on the adoption of active surveillance for low-risk prostate cancer.
Frendl DM; Sokoloff MH
Med Care; 2014 Jul; 52(7):576-8. PubMed ID: 24926703
[No Abstract] [Full Text] [Related]
16. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
17. Seeking the Truth: Understanding the Impact of Missing Data on the Validity of the New Surveillance, Epidemiology and End Results Prostate with Watchful Waiting Database.
Laviana AA; Luckenbaugh AN; Wallis CJD
Eur Urol; 2020 Sep; 78(3):345-346. PubMed ID: 32059823
[No Abstract] [Full Text] [Related]
18. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
19. The inconveniences of active surveillance in prostate cancer.
Sánchez-de-Badajoz E
Actas Urol Esp; 2016 Mar; 40(2):69-71. PubMed ID: 26341888
[No Abstract] [Full Text] [Related]
20. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
